BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
110.88
+0.11 (0.10%)
At close: Aug 22, 2025, 4:00 PM
110.16
-0.72 (-0.65%)
After-hours: Aug 22, 2025, 4:47 PM EDT
BioNTech SE Employees
BioNTech SE had 6,772 employees as of December 31, 2024. The number of employees increased by 639 or 10.42% compared to the previous year.
Employees
6,772
Change (1Y)
639
Growth (1Y)
10.42%
Revenue / Employee
$499,171
Profits / Employee
-$59,795
Market Cap
26.66B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BNTX News
- 15 days ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters
- 17 days ago - These Analysts Revise Their Forecasts On BioNTech After Q2 Results - Benzinga
- 18 days ago - BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga
- 18 days ago - BioNTech Stock Rises as Drug Maker Beats Earnings Expectations. - Barrons
- 18 days ago - BioNTech's Q2 revenues double on higher COVID vaccine sales - Reuters
- 18 days ago - BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 21 days ago - Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent - Fast Company